Retina

deepeye TPS is designed to close the gap between real-world outcomes and trial data by reducing patient dropout.

The results of an investigation into iRORA identified a wide spectrum of fundus autofluorescence patterns that corresponded with iRORA lesions and that those patterns were associated with conversion to cRORA over time.

Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months

New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.

DREAM is an acronym for deep imaging depth, rapid sweeping speed, extensive scan range, accurate results, and multimodal imaging capabilities.

In total, 613,690 images used for screening were included in the study.

The recent study details the diagnostic value of a multimodal model utilizing both types of biomarkers when compared with unimodal models.

The system was taught quality standards by being fed more than 1400 images from different parts of the retina taken by adaptive-optics ophthalmoscopy.

The drug was previously approved for high blood pressure in 1955.

Topline results from the MAGNIFY phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

With the acquisition, Topcon Healthcare also assumes RetInSight’s AI algorithms that analyze retinal images to detect and monitor disease.

The company said it will be available on the US market for use in clinics and healthcare institutions.

The optimal triple-carotenoid supports daily eye health with lutein, zeaxanthin, and meso-zeaxanthin, according to the company.

The starry faculty has a galaxy of symposia planned for May 4, 2025.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

The supplemental BLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and for broadening the dosing schedule to include every-4-week dosing across approved indications.

Good safety profile and “meaningful improvement” in vision in patient with Leber congenital amaurosis.

A Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025, was set by the organization.

Methylphenidate is a central nervous system stimulant that is used to treat ADHD, a very common diagnosis in children in the US.

Management strategies for patients with ocular syphilis primarily involve antibiotic treatment achieved using high-dose intravenous or intramuscular penicillin.

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

CRU Cofounder John Gelles, OD, gives his first impressions on how the conference is going thus far in Napa, California.

Researchers developed eye drop formulations 17-mer and H105A, both containing a short peptide, to administer to mice in the form of a drop on the eye’s surface.

The Retina Institute of Illinois is led by 9 physicians who have been providing comprehensive eye care in Illinois for almost 25 years.

Researchers set out to determine the age groups for which a polygenic risk score would most effectively predict glaucomatous risk and help inform cost-effective methods for disease detection.

ENCELTO is the first and only FDA-approved treatment for MacTel.

Julie Rodman, OD, MS, FAAO, sits down with Optometry Times to discuss her anticipation for the future of technology in optometry, especially retinal care.